TrialJournal of neuro-oncology2017

Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma.

Kathryn M Field et al.PubMed ↗Publisher ↗

No numbers read from the abstract.